Management of advanced HIV disease with no other complications in women and in Africans

International Journal of Clinical Practice

Volumn 61, Issue 1, 2007, Pages 119-129

  Williams, Ian ^a   Churchill, D ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STAVUDINE PLUS DIDANOSINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICAN AMERICAN; ANEMIA; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMIGRANT; IRELAND; LACTIC ACIDOSIS; NEURAL TUBE DEFECT; NEUTROPENIA; PATIENT COMPLIANCE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; UTERINE CERVIX CANCER; VIRUS LOAD;

AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CERVICAL INTRAEPITHELIAL NEOPLASIA; DECISION MAKING; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEX FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33847041076     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01236.x     Document Type: Review

References (45)

1. Girardi E, Sampaolesi A, Gentile M et al. Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. J AIDS 2000; 25: 71-6.
2. Neal JJ, Fleming P. Frequency and Predictors of Late HIV Diagnosis in the United States, 1994 Through 1999. Seattle, Washington: 9th Conference on Retroviruses and Opportunistic Infections, 2002, 24-28 February 2002 (Poster 474-M).
3. Sullivan AK, Curtis H, Sabin A et al. Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005; 330: 1301-2.
4. Palella FJ, Deloria-Knoll M, Chmiel JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138: 620-6.
5. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) Guidelines for the Treatment of HIV-infected Adults with Antiretroviral Therapy: an Update. April 2005. London: BHIVA, 2005.
6. Egger M, May M, Chene G et al. for the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
7. Phillips AN, Staszewski S, Weber R et al. for the Swiss HIV Cohort Study, the Frankfurt HIV Clinic Cohort, and the EuroSIDA Study Group. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-7.
8. Sabin C A, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-51.
9. Chene G, Sterne JA, May M et al. Prognostic importance of Initial responses in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679-86.
10. Colette JS, Sabin CA, Lampe FC et al. The relationship between CD4 count nadirs and the toxicity profile of antiretroviral regimens. Antivir Ther 2005; 10: 459-67.
11. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363: 1253-63.
12. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46.
13. Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368: 476-82.
14. Riddler SA, Haubrich R, DiRienzo G et al. A Prospective Randomised Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection: ACTG 5142. Toronto: IAC August 2006, 2006, Abstract: THLB0204.
15. 3) Using a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)- or a Boosted Protease Inhibitor (PI)- based Antiretroviral Therapy Regimen: 48-week Results (the ADVANZ Trial). Washington, DC: 44th Interscience Conference on Antimicrobacterial Agents and Chemotherapy (ICAAC), 2004, 30 October-2 November 2004 (H-574).
16. Pulido F, Arribas JR, Miro JM et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients with advanced HIV infection (EfaVIP 2 study). J AIDS 2004; 35: 343-50.
17. Joint United Nations Programme on HIV/AIDS: Report on the Global HIV/AIDS Epidemic July 2004- Bangkok report. http:// www.unaids.org/en/ publications'.
18. Health Protection Agency: HIV new diagnoses quarterly surveillance tables, UK data received to end of June 2004. http://www.hpa. org.uk.
19. Health Protection agency: Centre for Infections. Personal communication with Valerie Tesler. Data sourced from HIV new diagnoses quarterly surveillance tables UK. http://www.hpa.org.uk.
20. Curtis H, Sabin CA, Johnson MA. for the British HIV Association Clinical Audit Committee. Findings from the first national clinical audit of treatment for people with HIV. HIV Med 2003; 4: 11-7.
21. Health Protection Agency: Centre for Infections: National Study of HIV in Pregnancy and Childhood, data to end September 2005 (slide set). http//http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/ hiv/epidemiology/introduction.htm.
22. Health Protection Agency: Centre for Infections. Mapping the Issues: HIV and Other Sexually Transmitted Infections in the United Kingdom. London: HPA, 2005. http://www.hpa.org.uk/hpa/ publications/hiv_sti_2005/ (accessed 11 May 2006).
23. Food and Drug Administration. Important Drug warning; Zerit and Videx. USA Food and Drug Administration. Important drug warning: Zerit and Videx, 5th January 2001. http//http://www.fda.gov/ medwatch/safety/2001/ pregwarnfinalbms.pdf
24. Bristol-Myers Squibb. Sustiva: Package Insert. New York: Bristol- Myers Squibb, 2005.
25. Bristol-Myers Squibb. Sustiva: Summary of Product Characteristics. Hounslow: Bristol-Myers Squibb, 2005.
26. Clifford GM, Polesel J, Rickenbach M et al. for the Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 407-9.
27. Schafer A, Friedman W, Mielke M et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164: 593-9.
28. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003; 15: 382-8.
29. Fruchter RG, Maiman M, Sedlis A et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87: 338-44.
30. Department of Health. Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme. London: DH, 2004. http://www.cancerscreening.nhs.uk/cervical/publications/ 13 nhscsp20.html (accessed May 2006).
31. Matthews GV, Bower M, Mandalia S et al. Changes in acquired immunodeficiency-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-4.
32. Heard I, Potard V, Foulot H et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J AIDS 2005; 39: 412-8.
33. Health Protection Agency: Centre for Infections. Mapping the Issues: HIV and Sexually Transmitted Infections in the United Kingdom. London, 2005. Powerpoint® presentation. http://www.hpa.org.uk/ hpa/publications/ hiv_sti_2005/ppt/MtI_full_set.ppt#63 (accessed 14 May 2006).
34. Forsyth SF, Burns FM, French PD. Conflict and changing patterns of migration from Africa: the impact on HIV services in London, UK. AIDS 2005; 19: 635-7.
35. Del Amo J, Petruckevitch A, Phillips A et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12: 1203-9.
36. Burns FM, Fakoya AO, Copas AJ et al. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001; 15: 2453-5.
37. Health Protection Agency: Centre for Infections. The National CD4 Surveillance Scheme. London: HPA, 2004. http://www.hpa. org.uk/infections/ topics_az/hiv_and_sti/hiv/epidemiology/cd4.htm#5 15 (accessed May 2006).
38. Staehelin C, Rickenbach M, Low N et al. Migrants from sub- Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17: 2237-44.
39. Loveday C, Burke A, Van Hooff F et al. Equivalence in Virological Responses to HAART in Patients with HIV-1 Subtype Non-B Infections: a Case-controlled Study (n = 100). Chicago, Illinois: 8th Conference on Retroviruses and Opportunistic Infections, 2001, 4-8 February 2001 (Abstract 526).
40. Frater AJ, Beardall A, Ariyoshi K et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15: 1493-502.
41. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-46.
42. Pillay D, Walker AS, Gibb DM et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002; 186: 617-25.
43. De Wit S, Boulme R, Poll B et al. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS 2004; 18: 2330-1.
44. R-Novoa S, Barreiro P, Rendon A et al. G516T Polymorphism at the CYP2B6 Isoenzyme Significantly Influences Efavirenz Plasma Levels and the Risk of Neurological Symptoms. Boston, Massachusetts: 12th Conference on Retroviruses and Opportunistic Infections, 2005, 22-25 February 2005 (Abstract 652).
45. Haas D, Ribaudo H, Kim R et al. A Common CYP2B6 Variant is Associated with Efavirenz Pharmacokinetics and Central Nervous System Side Effects: AACTG Study NWCS214. San Francisco, California: 11th Conference on Retroviruses and Opportunistic Infec17 tions, 2004. 8-11 February 2004 (Oral presentation 133).